Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06676449 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06676449 · ClinicalTrials.gov record · last posted 2026-01-07

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

StatusRecruiting
PhasePhase 3
Started2024-11-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical trial is to learn if immunotherapy in combination with tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) and chemotherapy works to treat locally advanced esophageal squamous cell cancer in adults. Researchers will compare immunotherapy in combination with TDLN-sparing RT and chemotherapy to TDLN-sparing RT and chemotherapy to see if immunotherapy works more effectively when using TDLN-sparing RT to treat locally advanced esophageal squamous cell cancer Participants will: TDLN-sparing RT for esophageal cancer 50.4Gy/28Fx Paclitaxel plus cisplatin every 3 weeks for 4 cycles PD-1 inhibitors or observation every 3 weeks for 1 year

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-11-05; most recent amendment 2026-01-05. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06676449
Lead Sponsor Fudan University
Conditions Esophageal Carcinoma, Radiotherapy, Immunotherapy
Enrollment 432 participants
Start Date 2024-11-01
Primary Completion 2028-10-31 (estimated)
Study Completion 2030-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-07